EIF2AK3 and hepatocellular carcinoma: Most recently analysis of therapy-naïve HCC tissue has shown that baseline tissue expression of pERK and VEGFR-2, both key molecules in the cancerogenic pathway of HCCs, is inversely correlated with the clinical outcome in advanced HCCs treated with Sorafenib [47].